Other News To Note

• Atlab Pharma SAS, of Nantes, France, and BZL Biologics LLC, of New York, entered a sublicense agreement to develop (177)Lu-J591 as a prostate cancer treatment. The agreement includes exclusive rights to manufacture, develop and commercialize the radiopharmaceutical worldwide, as well as a joint Phase IIb/III program. Atlab will fund certain product development and clinical trials, but no financial terms were disclosed.